Enlivex Therapeutics’ (ENLV) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Enlivex Therapeutics (NASDAQ:ENLV) in a research report sent to investors on Friday morning,Benzinga reports. The brokerage currently has a $13.00 price objective on the stock.

A number of other analysts also recently commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Enlivex Therapeutics in a report on Tuesday, September 2nd. Wall Street Zen upgraded shares of Enlivex Therapeutics to a “sell” rating in a report on Saturday, August 30th. Two research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $10.00.

Enlivex Therapeutics Price Performance

ENLV opened at $1.07 on Friday. Enlivex Therapeutics has a twelve month low of $0.81 and a twelve month high of $2.10. The company has a 50-day moving average price of $1.24 and a 200 day moving average price of $1.10. The company has a market cap of $25.31 million, a PE ratio of -1.84 and a beta of 0.83.

Hedge Funds Weigh In On Enlivex Therapeutics

A hedge fund recently raised its stake in Enlivex Therapeutics stock. Jane Street Group LLC increased its stake in shares of Enlivex Therapeutics Ltd. (NASDAQ:ENLV) by 527.4% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 80,759 shares of the company’s stock after purchasing an additional 67,886 shares during the period. Jane Street Group LLC owned approximately 0.34% of Enlivex Therapeutics worth $78,000 at the end of the most recent reporting period. 1.02% of the stock is currently owned by hedge funds and other institutional investors.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.